title: [Clinical Efficacy of Sorafenib Combined with Low Dose Cytarabine for Treating Patients with FLT3+ Relapsed and Refractory Acute Myeloid Leukemia].
abstract: OBJECTIVE
  To study the efficacy and safety of sorafenib combined with low dose cytarabine for treating patients with FLT3(+) relapsed and refractory acute myeloid leukemia (FLT3(+) RR-AML).
  
  
  METHODS
  Seven patients with FLT3(+) RR-AML were treated with sorafenib and low dose cytarabine. The curative rate and adverse effects were observed in these patients.
  
  
  RESULTS
  Out of 7 RR-AML patients after treatment, 5 patients achieved complete remission (CR), 2 patients achieved partial remission (PR), and the overall response rate (ORR) after one course of therapy was 100%. No severe bleeding, nausea, vomiting and other side effects were found in these patients.
  
  
  CONCLUSIONS
  Sorafenib combined with low dose cytarabine can effectively induce the remission of FLT3(+) RR-AML patients, and is worth for further clinical trails to verify its safty and efficiency.
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, Guangdong Province, China.
authors.forename: Xiao-Shu
authors.initials: XS
authors.lastname: Liu
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, Guangdong Province, China.
authors.forename: Hui
authors.initials: H
authors.lastname: Long
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, Guangdong Province, China.
authors.forename: Yu-Xian
authors.initials: YX
authors.lastname: Huang
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, Guangdong Province, China.
authors.forename: Jian-Hui
authors.initials: JH
authors.lastname: Xu
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, Guangdong Province, China.
authors.forename: Jun-Yu
authors.initials: JY
authors.lastname: Zhu
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, Guangdong Province, China.
authors.forename: Qing-Feng
authors.initials: QF
authors.lastname: DU
authors.affiliation: Department of Hematology, Zhujiang Hospital of Southern Medical University, Guangzhou 510282, Guangdong Province, China. E-mail: wubingyi@aliyun.com.
authors.forename: Bing-Yi
authors.initials: BY
authors.lastname: Wu
mesh_terms: D003561:Cytarabine / Q000627:therapeutic use*; D006801:Humans; D015470:Leukemia, Myeloid, Acute / Q000188:drug therapy*; D009536:Niacinamide / Q000031:analogs & derivatives* / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use*; D012008:Recurrence; D012074:Remission Induction; D000077157:Sorafenib; D016896:Treatment Outcome; D051941:fms-Like Tyrosine Kinase 3 / Q000378:metabolism
chemical_list: D010671:Phenylurea Compounds; D003561:Cytarabine; D009536:Niacinamide; D000077157:Sorafenib; C497970:FLT3 protein, human; D051941:fms-Like Tyrosine Kinase 3